DiaSorin Launches New Liaison HIV HT, Confirming Its Commitment in the Blood Banks Market

7 Oct 2014
Sarah Thomas
Associate Editor

Product news

DiaSorin today strengthens its presence in the Blood Banks market through the launch of the new test LIAISON XL murex HIV Ab/Ag High Throughput (HT) outside the USA and Canada.

The strategy of DiaSorin in Blood Banks has developed through the acquisition from Abbott in 2010 of MUREX, the leading brand of Blood Banks, and through the development and marketing of the complete menu for Blood Banks on the platform LIAISON XL.

DiaSorin today offers the most extensive menu of technology combined CLIA and ELISA in the market.

This strategy has allowed DiaSorin to penetrate important markets such as Latin America, Asia-Pacific and Europe, which have a total estimated value, with regard to the Immunodiagnostic, of approximately 400 million Euro. For example DiaSorin holds a significant market share in Brazil, Mexico, Malaysia, Taiwan and observes a continuous growth in key European countries.

In recent weeks, DiaSorin has won an important tender with the Red Crescent in Turkey, an organization that represents almost all of the donations in the country and expects 29 million tests over the next 3 years. This success confirms the appreciation for DiaSorin’s solutions by Blood Banks.

The launch of the new test LIAISON XL murex HIV Ab / Ag high-throughput (HT) enhances the offer and competitiveness of DiaSorin for the Blood Banks of medium and large size.

In fact, the test is able to offer a high operating efficiency, arriving at an hourly productivity of 171 tests on LIAISON XL, and at the same time to remain one of the most sensitive tests available on the market today with a good level of specificity.

The ability to perform tests with high productivity and diagnostic accuracy is of fundamental importance for Blood Banks, which have to perform a defined protocol of tests to ascertain the presence of HIV, Hepatitis B and C, while respecting the response time.

It is also estimated that worldwide 35 million people are currently infected with HIV, a virus that is transmitted through sexual contact between HIV-positive individuals, with exposure to contaminated blood, with the prenatal infection of a fetus or with the perinatal infection of a newborn from an infected mother. HIV continues to cause every year 2.1 million new infections and 1.5 million deaths, representing, along with hepatitis, a real health emergency in some areas of the planet.

Links

Tags

Blood TransfusionBlood Transfusion involves giving donor blood to a recipient patient. Screening is essential to avoid transfusion reactions. Blood banks use immunohematological techniques to determine rh and ABO blood group, and screen for antibodies using specific antisera. Blood Banks use Direct Coombs Tests (DCT) and Indirect Coombs Tests (IAT) to detect hemolysis and Haemolytic Disease of the Newborn (HDN).Robotic InstrumentsRobotic instruments can be used for high-throughput automation of many lab processes. Such processes use instruments for assays like cell based assays and ELISA, for sample preparation like shakers, centrifuges and incubators, and for analysis such as sequencing and western blot analyzers. Useful features of robotic instruments include speed, reproducibility, barcode readers, software and automation.HIV and AIDSBlood tests are the most common way to identify and monitor HIV and AIDS. Current methods include ELISA, Western blot, RT-PCR viral load and CD4/8 testing. Areas for development include point-of-care assays for use in developing countries, and self-testing ‘at home’ HIV kits.Blood AnalysisThe analysis of blood is vital for many areas of life sciences and forensic investigations. Blood samples can be tested for a number of different reasons such as diagnosis, glucose levels, cholesterol and drug testing.
DiaSorin Launches New Liaison HIV HT, Confirming Its Commitment in the Blood Banks Market